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Abstract Vascular endothelial growth factor (VEGF) mRNA 
expression was analysed in rabbit vascular smooth muscle cells 
following exposure to hypoxia and platelet-derived growth factor- 
BB (PDGF-BB). Hypoxia potently upregulated VEGF mRNA 
steady-state l vels in a time- and concentration-dependent man- 
ner reaching a maximum level (~30-fold increase) after 12-24 h 
at 0% 02. In contrast, PDGF-BB caused a modest increase in 
VEGF expression. However, the combination of PDGF-BB and 
a threshold hypoxic stimulus (2.5% O2 for 4 h) had a marked 
synergistic effect. Synergy between hypoxia and PDGF-BB was 
selective for VEGF expression as hypoxia had no effect on the 
PDGF-induced upregulation of the proto-oncogene c-myc. These 
results raise the possibility that hypoxia and PDGF-BB may act 
in concert to induce VEGF expression in the arterial wall during 
the development of atherosclerosis. 
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derived growth factor-BB (PDGF-BB) and by transforming 
growth factor-fl [11,12]. VEGF is a highly specific mitogen for 
endothelial cells [13]. Also, it increases vascular permeability 
[14] and stimulates monocyte migration through endothelial 
layers [15]. These events may be important in the initiation and 
progression of atherosclerosis, a process which is driven by 
multiple growth factors and cytokines [1]. Within the vessel wall 
these regulatory molecules are likely to interact simultaneously 
with physicochemical changes of the local microenvironment 
such as hypoxia. We therefore hypothesised that these diverse 
stimuli may act in concert o induce VEGF expression. In this 
paper we report that a reduction in oxygen tension in rabbit 
VSMC leads to a rapid and marked induction of VEGF 
mRNA. We also demonstrate hat PDGF-BB, which on its own 
causes a modest upregulation of VEGF mRNA expression, in 
combination with a threshold hypoxic stimulus potently upreg- 
ulates the expression of this molecule. 
2. Materials and methods 
I. Introduction 
Vascular smooth muscle cells (VSMC) are the main cellular 
component of the normal arterial wall and have a major role 
to play in atherogenesis [1]. These cells form a distinct muscular 
layer, the tunica media, which is largely avascular [2]. Oxygen- 
ation is by direct diffusion from the lumen and from the ad- 
ventitial vasa vasorum [3,4]. Changes in the anatomy of the 
blood vessel wall such as intimal thickening or occlusion of the 
vasa vasorum may alter the distribution of oxygen sufficiently 
to render the tunica media hypoxic [5,6]. Hypoxia of the arterial 
wall has been implicated in the pathogenesis of atherosclerosis 
[5,6] but the molecular events induced in VSMC by reduced 
oxygen tension are largely unknown. 
Vascular endothelial growth factor (VEGF; also known as 
vascular permeability factor) is a secreted angiogenic factor [7] 
which has been implicated in the neovascularisation f solid 
tumours [8,9]. VEGF is strongly induced by hypoxia in cultured 
cells, including tumour cell lines [9] and cardiac myocytes [10]. 
In addition, it can be induced in cultured fibroblasts by platelet- 
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2,1. Materials 
Tissue culture media and additives were from Gibco Life Technolo- 
gies, Paisley, Scotland, UK and foetal calf serum (FCS) from Sigma, 
UK. Duralon-UV membranes and QuickHyb solution were from Strat- 
egene. Radiolabelled nucleotides and Megaprime DNA labelling sys- 
tem were from Amersham Int., UK. Other items were from standard 
suppliers or as listed in the text. 
2.2. Cell culture 
Primary cultures of VSMC were grown by the explant echnique 
[16,17]. One mm z explants from the tunica media of the thoracic aorta 
of New Zealand White rabbits were cultured in 100 mm-diameter tissue 
culture dishes (Costar Corp., Cambridge, MA) in the presence of Dul- 
becco's modified Eagle's medium (DMEM) containing 20% FCS, 0.1 
mM non-essential mino acids, 1 mM sodium pyruvate, 4 mM 
L-glutamine, 100 units/ml penicillin and 100 ¢tg/ml streptomycin. Cul- 
tures were grown at 37°C under 5% COJ95% air in a humidified 
incubator. For experiments, emi-confluent explant cultures were tryp- 
sinized and the cells subcultured in 100 mm-diameter dishes at a density 
of 5 × 105 cells/dish. When the cultures became confluent (usually 4-5 
days after plating) the medium was replaced with DMEM containing 
0.5% FCS and the cells were incubated for a further 48 h to render them 
quiescent prior to the initiation of each experiment. 
2.3. Hypoxic onditions 
Experiments at low oxygen tensions were performed in a custom 
made, air-tight, humidified environmental chamber (Wellcome Re- 
search Laboratories, Beckenham, Kent, UK) maintained at37°C and 
flushed with a mixture of 5% CO 2 and 02 in the range of (~5%, the 
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3. Results balance made up with N2. The oxygen concentration inside the chamber 
was monitored by an oxygen electrode (Russell pH Ltd., Fife, Scotland, 
UK) immersed in a stirred water bath. The electrode was connected via 
an oxygen meter (Grffin&George, Loughborough, UK) to a custom 
made electronic gas controller which, continuously throughout the ex- 
periment, monitored and automatically adjusted the oxygen concentra- 
tion to the desired preset level. 
2.4. Northern blot analysis 
Cell monolayers were washed twice with ice-cold PBS and total 
cellular RNA extracted according to the acid guanidinium thiocyanate/ 
phenol/chloroform ethod [18] using 2 ml per dish of RNAzol B 
(Cinna/Biotecx Laboratories Inc., Houston, TX). RNA (20/2g per lane) 
was electrophoresed on 1% agarose/6% formaldehyde gels and trans- 
ferred to Duralon-UV membranes using a positive pressure blotter 
(Strategene Ltd., Cambridge, England, UK). Hybridisations were per- 
formed at 64°C for one hour in QuickHyb Solution (Strategene) con- 
taining 0.1 mg/ml denatured salmon sperm DNA and 1.5~ x 106cpm] 
ml 32P-labelled cDNA probes (specific activity of 0.5-1 × 109 cpm//2g) 
made by random priming using [~-32p]dCTP. The following DNA tem- 
plates were used for random priming: a 540 base pair BamHI-HindIII 
fragment of human VEGF121cDNA [19], a 850-base pair PstI-HindIII 
fragment (nucleotides 540 to 1390) of human c-myc cDNA (kindly 
provided by Dr. H. Land, Imperial Cancer Research Laboratories, 
London, UK) and a 1100-base pair fragment of human glyceraldehyde- 
3-phosphate dehydrogenase (GAPDH) cDNA (Clontech Laboratories, 
Palo Alto, CA). Following hybridisation, filters were washed in 
1 × SSC/0.1% SDS for 15 min at room temperature and then for 15 rain 
at 55°C. Filters were autoradiographed and the resulting bands 
quantified by densitometry. To verify the relative amount of total 
RNA filters were stripped and hybridised with a 28S rRNA anti- 
sense oligonucleotide probe (Clontech Laboratories) (0.2 × 106 cpm/ml) 
labelled by phosphorylation with [T-32P]ATP using T4 polynucleotide 
kinase (Gibco BRL). Each experiment was performed at least 
three times and the results from one representative experiment are 
shown. 
2.5. Reverse transcriptase-polymerase chain reaction analysis of RNA 
Synthesis of cDNA templates for PCR analysis was carried out for 
one hour at 37°C in a final reaction volume of 20/21 containing 1/2g 
total cellular RNA sample, l0 mM DTT, 0.5 mM dNTPs, 3.6 /2g 
random hexamer primers (Boehringer-Mannheirn), 17 units 
RNAguard (Pharmacia), 100 units Superscript reverse transcriptase 
(Gibco BRL) and buffer supplied by the manufacturer of the enzyme. 
The cDNA contained in 1/21 aliquots of the reverse transcriptase r ac- 
tion was amplified in a 50/21 reaction using a Perkin Elmer 9600 thermal 
cycler and Amplitaq DNA polymerase (Perkin-Elmer Cetus) as de- 
scribed by the manufacturer. The oligonucleotide primers used for 
amplification of VEGF cDNA, 5'-CTGCTCTCTTGGGTG- 
CACTGG-3' (5'-primer) and 5'-CACCGCCTTGGCTTGTCACAT-3' 
(3'-primer), were derived from the coding region of the rat cDNA 
sequence [20]. The primers used for amplification offl-actin cDNA were 
5'-GAAACTACCTTCAACTCCATC-3' and 5"-CGAGGCCAGGA- 
TGGAGCCGCC-3'. The reaction was allowed to proceed for 25 cycles, 
each cycle consisting of 30 s at 94°C, 60 s at 55°C (for VEGF) or at 
60°C (for fl-actin), and 60 s at 72°C. Fifteen/21 aliquots of the PCR 
reactions were seperated on 1.5% agarose gels. VEGF PCR products 
were identified by Southern blot analysis using a murine 32p-labelled 
VEGF~64 cDNA probe [21]. 
A 
3.1. Hypoxia upregulates VEGF mRNA levels in vascular 
smooth muscle cells 
Exposure of confluent and quiescent rabbit VSMC to 0% Oz 
resulted in a marked time-dependent increase in the steady- 
state levels of a major 3.7 kb VEGF mRNA species (Fig. 1A). 
The rise in the expression of this transcript was detectable as 
early as 30 rain after incubation at 0% O2 and reached a max- 
imum level (30-fold increase) between 12-24 h. In contrast, the 
basal expression of VEGF mRNA in cells incubated at 21% 02 
was barely detectable and did not change during the 24 h period 
of incubation (Fig. 1A). It was consistently noted that hypoxia 
induced the expression of additional minor VEGF-related tran- 
scripts, the most prominent having a size of 1.5 kb. Hypoxia- 
induced VEGF expression was also dependent on the concen- 
tration of 02 (Fig. 1B). After 4 h at 5% 02, steady-state l vels 
of VEGF mRNA were not significantly different o levels de- 
tected at 21% 02, whereas below 5% 02 the level of expression 
increased markedly (> 3.5-fold). Similar results were obtained 
with human aortic VSMC (results not shown). Hybridisation 
to a GAPDH probe showed that the mRNA for this enzyme 
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2.6. Immunoprecipitations and Western blotting 
Phosphotyrosyl proteins were immunoprecipitated from cellular ly- 
sates with the anti-phosphotyrosine monoclonal ntibody (mAb) PY20 
(Transduction Laboratories Inc.) and resolved by polyacrylamide g l 
electrophoresis a previously descibed [22]. For immunoblotting of
PDGF-fl receptor, cellular proteins were solubilised by boiling intact 
cells directly in SDS sample buffer without immunoprecipitation. Fol- 
lowing protein transfer to Immobilon Membranes (Millipore Corp.), 
these were blocked using 5% non-fat dried milk in PBS and incubated 
for 2 h with 1 mg/ml of either PY20 mAb or anti-PDGF-fl receptor 
mAb (Transduction Laboratories Inc.) in PBS containing 0.05% 
Tween-20. Immunoreactive bands were visualized using 125I-labelled 
sheep anti-mouse IgG and autoradiographed. 
GAPDH 
rRNA 
Fig. 1. Upregulation of VEGF mRNA expression by hypoxia in rabbit 
VSMC. Cells were exposed to 0% 02 or 21% 02 for various lengths of 
time (A) or to various 02 tensions for 4 h (B) and then levels of mRNA 
expression were determined by Northern blot analysis. Filters were 
sequentially hybridised to VEGF, GAPDH and 28S rRNA 32p-labelled 
probes. 
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Fig. 2. Characterisation f VEGF transcripts upregulated by hypoxia in VSMC. Total cellular RNA was prepared from cells exposed to 0%, 1% 
or 21% 02 for 24 h and then analysed by reverse-transcriptase polymerase chain reaction. VEGF eDNA amplification products were visualised by 
Southern blot analysis using a 32p-labelled VEGF~64 eDNA probe, fl-Actin eDNA amplification was visualised by direct staining of the agarose gel 
with ethidium bromide. 
was also increased, but only following prolonged incubations 
(>4 h) at 0% 02 and to a much lesser degree (1.5 3-fold) than 
VEGF (Fig. 1A). Comparable loading of total RNA in each 
lane was therefore confirmed by hybridisation to a 28S ribo- 
somal RNA probe. 
Different isoforms of VEGF have been characterised which 
are products of alternatively spliced mRNA [21,23]. To investi- 
gate which VEGF isoforms were expressed by VSMC, we per- 
formed reverse-transcriptase polymerase chain reaction analy- 
sis of the RNA samples. Consistent with results obtained by 
Northern blot analysis, low levels of VEGF mRNA were pres- 
ent in VSMC incubated at 21% 02 (Fig. 2). In contrast, in RNA 
samples from VSMC incubated at 0% or 1% 0 2 for 24 h two 
prominent ranscripts of 563 bp and 431 bp, corresponding 
respectively to the sizes expected for VEGF164/165 and 
VEGFj2oa21, were detected (Fig. 2). These VEGF isoforms have 
been shown to be readily secreted by producer cells [21,23]. 
VEGF transcripts encoding the larger cell-associated isoforms 
were not detected. 
3.2. Hypoxia and PDGF-BB synergistically induce VEGF 
mRNA expression in vascular smooth muscle cells 
PDGF-BB has been reported to induce the expression of 
VEGF in NIH-3T3 fibroblasts [11]. This prompted us to inves- 
tigate the effect of PDGF-BB on VEGF mRNA expression i  
VSMC. Fig. 3 (top left panel) shows that incubation with 
PDGF-BB for 4 h at 21% 02 caused a dose-dependent i crease 
in VEGF mRNA expression. This increase was lower than that 
seen following incubation for 4 h at 0% Oz (Fig. I). Strikingly, 
the combination of PDGF-BB and a submaximal hypoxic stim- 
ulus (2.5% 02 for 4 h) caused an increase in the levels of VEGF 
mRNA to an extent hat was greater than the additive effect 
of the two respective stimuli alone. This synergistic effect was 
evident at all the concentrations of PDGF-BB tested but was 
most marked below 25 ng/ml (-2 times greater than the expected 
additive effect). Furthermore, synergistic enhancement of 
VEGF expression by hypoxia and PDGF-BB was also ob- 
served when cells were incubated for 1 h at 1% 02 (results not 
shown). 




VEGF c-myc rRNA 
Fig. 3. Synergistic upregulation ofVEGF mRNA expression by hypoxia nd PDGF-BB. Cells were incubated for 4 h with different concentrations 
of PDGF-BB either at 2.5% 02 or at 21% 02 and then levels of VEGF and c-myc mRNA expression were determined by Northern blot analysis. 
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In order to investigate whether the synergy between PDGF- 
BB and hypoxia was selective for VEGF mRNA expression, we 
examined the effect of PDGF-BB and hypoxia on the expres- 
sion of the proto-oncogene c-myc. In agreement with previous 
findings in a variety of cell types, PDGF-BB increased c-myc 
mRNA expression in quiescent rabbit VSMC in a concentra- 
tion-dependent manner (Fig. 3, top middle panel). This re- 
sponse was similar to that observed for induction of VEGF. 
However, in contrast to the synergistic enhancement of VEGF 
mRNA expression, c-myc expression was not enhanced by in- 
cubation at 2.5% 02 (Fig. 3, lower middle pannel) or 0% 02 
(results not shown). 
The observed synergistic stimulation of VEGF mRNA ex- 
pression could result from upregulation ofPDGF receptors. To 
test this possibility we examined the effect of hypoxia on the 
expression of PDGF-fl receptors and on receptor auto- 
phosphorylation. Incubation of VSMC in 0% 02 for 4 h or 
12 h caused no increase in the expression of the PDGF-fl recep- 
tor as determined by Western blotting (results not shown). In 
addition, exposure of cells to 0% Oz for 4 h followed by treat- 
ment with 25 ng/ml PDGF-BB for 10 min and Western blotting 
with an anti-phosphotyrosine mAb showed that hypoxia had 
no effect on the stimulation of PDGF receptor auto- 
phosphorylation (results not shown). 
4. Discussion 
The cells involved in atherosclerosis are known [1]. The mo- 
lecular events induced in these cells during the initiation and 
progression of the disease remain unclear. Animal models of 
atherosclerosis have implicated the luminal endothelium as an 
initial mediator of this process but there has been little investi- 
gation into the initiating role of VSMC. Evidence has accumu- 
lated that hypoxia within the tunica media of the arterial wall 
may be one of the many microenvironmental factors that medi- 
ates the early events involved in atherogenesis [5,6,24,25]. 
The present study demonstrates that hypoxia induces a 
marked concentration-dependent and ime-dependent i crease 
in the expression of VEGF mRNA in rabbit VSMC and that 
hypoxia can act in synergy with PDGF-BB in the upregulation 
of this transcript. This effect was selective for VEGF as hypoxia 
had no effect on PDGF-induced expression of the growth- 
regulated proto-oncogene c-myc. We have verified that hypoxia 
neither altered the level of PDGF-fl receptor expression nor the 
level of PDGF receptor autophosphorylation n rabbit VSMC. 
It is therefore unlikely that the observed synergy between 
PDGF-BB and hypoxia was indirectly due to an increase ither 
in the number of PDGF receptors or the activity of PDGF 
receptor protein tyrosine kinase. The human VEGF gene pro- 
moter region contains a specific hypoxia-sensitive region with 
no significant homologies to other transcriptional control ele- 
ments (Dr. Peter Ratcliffe, John Radcliffe Hospital, Oxford, 
UK; personal communication) and also several potential AP-1 
and AP-2 binding sites [19]. PDGF activates c-AMP and pro- 
tein kinase-C signal transduction pathways [26] and both these 
pathways have been directly implicated in the induction of 
VEGF expression [11]. Thus the synergy between PDGF-BB 
and hypoxia could be a manifestation of the activation and 
cooperation of several transcriptional control elements timu- 
lated by multiple signal transduction mechanisms. 
Brogi et al. recently reported that hypoxia regulates VEGF 
mRNA expression in human VSMC [27]. These workers only 
examined VEGF expression i  cells exposed to severe hypoxia 
for prolonged periods of time (24 48 h) and did not investigate 
the combined effect of hypoxia and individual growth factors. 
In contrast, the present work examined synergistic nteractions 
between hypoxia and PDGF-BB under less extreme hypoxic 
conditions for relatively short time periods (2.5% 02 for 4 h). 
These experimental conditions may more closely represent the 
local microenvironment within the tunica media in vivo, thus 
suggesting a mechanism by which the hypoxic arterial wall 
could modulate ndothelial cell function. 
'Response to endothelial injury' theories of atherosclerosis 
have stressed the initiating role of the endothelium by acting 
as a source of regulatory molecules which modulate the func- 
tion of VSMC [1]. Much less attention has been given to the 
response of medial VSMC to physicochernical changes in the 
arterial wall, such as hypoxia. Induction of VEGF by hypoxia 
may promote early atherogenesis both through its effect on 
endothelial permeability and by a direct effect on monocyte 
migration. VEGF may also be involved in the advanced stages 
of atherosclerosis as a result of its angiogenic properties. Detec- 
tion of VEGF mRNA in human coronary atherosclerotic 
lesions by in situ hybridisation [28] supports this possibility. 
Furthermore, neovascularisation f complex plaque is well 
described in the literature [29,30] and may contribute to the 
clinical presentation of acute ischaemic syndromes. Our obser- 
vation that VEGF expression i  VSMC is exquisitely sensitive 
to both hypoxia nd PDGF is entirely consistent with a role for 
VEGF in the aetiology of atherosclerosis. 
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